BMRN BioMarin Pharmaceutical Inc. | US09061G1013
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 4.427.389.840 | 3.872.963.960 | 14.32% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 6,39 | 4,93 | 29.59% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 16 | 17 | 5.88% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |